Pharmaceuticals

Artelo's latest data on its non-opioid pain drug ART26.12 could unlock a massive market, but what are the real risks and rewards for this clinical-stage biotech?

Vyome Holdings secures a key patent in China, not by betting the farm, but by making a shrewd, capital-efficient move to tap into a massive future market.

As Merck preps for its August 4th earnings call, investors look past Q2 numbers to see if a flurry of deals and pipeline wins can build a new empire.

As Sobi prepares its Q2 2026 report, all eyes are on its booming immunology unit. After a stellar Q1, the key test is sustaining that momentum.

Millions of older Americans can now access the popular weight-loss drug Wegovy for a $50 copay, a temporary move that could reshape healthcare policy and the pharma market.

Galderma's innovative neuromodulator, a key to its 'powerhouse' ambitions, hits a U.S. roadblock. The FDA's concerns? Manufacturing, not safety.

The FDA's approval of a potent new triglyceride drug comes with a staggering price tag, forcing a showdown with an established, affordable therapy.

Tiny, unlisted impurities in research chemicals can derail studies and undermine scientific integrity. A new analysis reveals the rigorous standards we should demand.

Once a quiet niche, the wAIHA market is now a battleground for J&J, Sanofi, and Novartis, with a 14.4% growth forecast and a new class of drugs.

UFC GYM's new PWR Clinics signal a tectonic shift in the wellness industry. Is this the future of fitness or a high-stakes bet on a regulatory minefield?

A new report reveals a massive strategic shift in obesity care. Pharma giants are pouring billions into FGF21, a new drug class aiming beyond weight loss.

Beyond a simple conference, Tsingke Biotech's recent salon was a strategic play to position itself as the linchpin in China's shift to biotech innovation.

A new collaboration between AustinPx and Thermo Fisher is scaling up KinetiSol, a breakthrough tech that makes insoluble drugs viable, promising greener paths to new therapies.

Kowa's pemafibrate gets FDA Breakthrough status for a rare liver disease. We dissect what this means for patients, the science, and the company's global strategy.

Millions suffer from chronic cough with no cure. A Boston biotech is testing a novel aerosol that targets the root cause, not just symptoms. Could it be the first disease-modifying treatment?

A new FDA pilot program with Japan's Kyowa Kirin aims to slash drug approval times. It's an operational innovation that could fix U.S. supply chains.

Artelo Biosciences uses advanced analytics to link its lead drug to a core disease pathway, a strategic move to de-risk development and attract major partners.

The world's only lupus-focused fund is betting on a new model blending VC rigor with patient-led strategy. But can this ambitious structure deliver real progress?

Sarepta seeks full FDA approval for two Duchenne drugs, leaning on real-world evidence after a key trial missed its goal. A test case for rare disease innovation.